Enzalutamide 160mg Tablet

Enzalutamide 160mg Tablet contains enzalutamide, a prescription androgen receptor inhibitor used in the treatment of certain types of advanced prostate cancer. It works by blocking androgen receptor signaling, which can help slow the growth and progression of prostate cancer cells.

Xtandi® is the reference brand containing enzalutamide. Enzalutamide products may be available under different brand names depending on the manufacturer and country.

Product Information

Generic Name

Enzalutamide 160mg

Drug Class

Androgen Receptor Inhibitor / Antiandrogen

Reference Brand

Xtandi®

Indication

Advanced Prostate Cancer

Form

Tablet

Strength

160mg

Route

Oral

Prescription

Yes

Active Ingredient

Enzalutamide

Packing

Manufacturer Dependent

Enzalutamide 160mg and Xtandi®

Xtandi® is the reference brand for enzalutamide. Enzalutamide 160mg Tablets contain the same active pharmaceutical ingredient, enzalutamide.

For SEO, the strongest primary product name is:

Enzalutamide 160mg Tablet

Supporting terms can include Generic Xtandi®, Xtandi alternative, Enzalutamide 160mg, Enzalutamide prostate cancer medicine, and Enzalutamide androgen receptor inhibitor where appropriate.

Availability & Ordering

Patients searching for Enzalutamide 160mg Tablet, Buy Enzalutamide Online, Enzalutamide 160mg Price, Generic Xtandi®, Xtandi Alternative, Enzalutamide Prostate Cancer Medicine, Enzalutamide Hormone Therapy, and Androgen Receptor Inhibitor can find prescription oncology medicines through licensed pharmaceutical suppliers, subject to local prescription and pharmaceutical regulations.

How it works

Enzalutamide blocks the androgen receptor signaling pathway. It interferes with androgen binding to the receptor and inhibits downstream receptor activity that can promote the growth and survival of prostate cancer cells.

By suppressing androgen receptor signaling, enzalutamide can help slow the progression of androgen-dependent prostate cancer.

Enzalutamide 160mg may be prescribed for eligible patients with certain forms of advanced prostate cancer, including:

• Metastatic castration-resistant prostate cancer (mCRPC)
• Non-metastatic castration-resistant prostate cancer (nmCRPC)
• Metastatic hormone-sensitive prostate cancer (mHSPC) in appropriate treatment settings

The approved indications and treatment combinations vary according to country, regulatory approval, and individual patient circumstances.